Vitamin C to Reduce Morning Cardiovascular Risk

Oregon Health & Science University (OHSU)

Status: Completed

Conditions: Cardiovascular Risk Factor

Treatments: Other: Placebo; Dietary Supplement: Vitamin C

Study type: Interventional

Funder types: Other

Identifiers

NCT03290612

IRB 00017294

Details and patient eligibility

About

This study will test the efficacy of Vitamin C to counteract morning cardiovascular (CV) risk markers in a randomized, double blind, placebo controlled crossover pilot study. The participants will also perform morning typical behaviors such as arousal from sleep, change in posture (getting out of bed) and mild intensity physical activity; identical to the stressors encountered in everyday life. Primary dependent variables are markers of cardiovascular risk including vascular endothelial function and oxidative stress.

Full description

The investigators plan to test the efficacy of Vitamin C to counteract morning cardiovascular (CV) risk markers in a randomized, double blind, placebo controlled crossover pilot study. The participants will also perform morning typical behaviors such as arousal from sleep, change in posture (getting out of bed) and mild intensity physical activity; identical to the stressors encountered in everyday life. This pilot study is in healthy middle aged adults without a history of CV disease.

Participants will spend two nights in an inpatient hospital suite at Hatfield Research Center. Upon awakening in the morning, they will either ingest Vitamin C or placebo in a randomized order. This will be followed by moderate intensity exercise, recovery, and discharge.

Enrollment: 10 patients

Sex: All

Ages: 40 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy participants
• Normal weight or overweight but not obese (18.5<BMI<33 kg/m2)

Exclusion criteria

• History of smoking/tobacco use
• Current prescription/non-prescription medications or drugs of abuse
• Acute, chronic, or debilitating medical conditions
• History of working irregular day and night hours, regular night work, or rotating shift work for the six months prior to the study.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

10 participants in 2 patient groups

Vitamin C then Placebo

Experimental group

Description:

Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.

Treatment:

Dietary Supplement: Vitamin C

Other: Placebo

Placebo then Vitamin C

Experimental group

Description:

Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.

Treatment:

Dietary Supplement: Vitamin C

Other: Placebo